Sennae foliolum cum fructu
7.5 mg of hydroxyanthracene derivatives, calculated as sennoside B, per tablet
The active compounds formed from the anthranoid glycosides contained in the leaves and fruits of senna
affect the peristalsis of the large intestine, inhibit water absorption, which causes softening of the fecal mass
and facilitates defecation.
A herbal medicine for short-term treatment of constipation.
The medicine should not be used in case of known hypersensitivity to the active substance, intestinal obstruction and
stricture, atony, appendicitis, inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), abdominal pain of unknown origin,
dehydration combined with electrolyte loss. The medicine should not be used in children under 12 years of age.
The product is not intended for long-term use. The decision to use it for a period longer than 1-2 weeks can be made by a doctor.
Taking laxative medicines for a longer period can disrupt the functioning of the intestines and cause dependence.
Preparations containing hydroxyanthracene glycosides should only be recommended when proper defecation cannot be achieved through dietary changes.
Do not use in patients with fecal impaction and gastrointestinal disorders, such as abdominal pain, nausea, and vomiting, unless the doctor decides otherwise.
Such symptoms may indicate the possibility of intestinal obstruction. In patients with renal function disorders, there is a risk of electrolyte imbalance.
Using the medicine in patients with fecal incontinence requires more frequent changing of diapers to avoid prolonged contact of feces with the skin.
Chronic abuse of the medicine can lead to hypokalemia (decreased potassium levels), which can then enhance the effect of concurrently administered cardiac glycosides, antiarrhythmic drugs, QT-prolonging drugs, and sinus rhythm-restoring drugs.
Concomitant use of the preparation with drugs that cause hypokalemia, such as diuretics, adrenal cortex steroids, licorice root, may exacerbate electrolyte deficiency.
Do not use in children under 12 years of age.
Pregnancy and Breastfeeding:
There is a lack of sufficient data on the use during pregnancy, therefore, it is not recommended to use it during this period.
It is not recommended to use during breastfeeding, due to the lack of sufficient data on the penetration of metabolites into milk.
Small amounts of active metabolites (rein) penetrate into the milk of breastfeeding women, however, no laxative effect has been observed in infants.
Driving and Operating Machines:
No effect.
Route of Administration:Oral.
Senefol, 2024.10.18
1 / 2
Dosage:Adolescents over 12 years of age, adults: 2-4 tablets before bedtime.
The preparation should be taken with a large amount of water. Do not exceed the dose of 4 tablets.
Due to individual sensitivity, dosing should be started with the smallest dose (1 tablet), which should be increased if necessary to determine the effective dose.
The laxative effect occurs after a period of 8 to 12 hours, in case of its absence, the next dose of the preparation should be taken after 12 hours.
Taking the medicine 2-3 times a week is usually sufficient to achieve a therapeutic effect.
Cramping, diarrhea, with the possibility of dehydration and electrolyte loss (water and electrolyte imbalance) may occur.
It is necessary to balance the water and electrolyte deficit. It is recommended to monitor potassium levels, especially in the elderly.
Prolonged overdose of anthranoids can lead to liver inflammation.
A double dose should not be used to make up for a missed dose.
In individuals hypersensitive to the preparation's ingredients, allergic reactions may occur, including itching, hives, rash.
Cramping and abdominal pain may occur. The used dose should then be reduced.
Long-term use of the medicine may cause dark discoloration of the colonic mucosa (pseudomelanosis coli), which usually disappears after the end of the treatment.
The possibility of changing the urine color with metabolites (to pink or reddish-pink, depending on pH) has no clinical significance.
Reporting Adverse Reactions:
If any adverse reactions occur, including any adverse reactions not listed in this leaflet, you should inform your doctor or pharmacist, or nurse.
Adverse reactions can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309.
Website: https://smz.ezdrowie.gov.pl.
Adverse reactions can also be reported to the marketing authorization holder. By reporting adverse reactions, more information can be collected on the safety of the medicine.
Store in closed packaging, at a temperature up to 25°C, in a place invisible and inaccessible to children.
Do not use the medicine after the expiration date stated on the packaging.
Sennae foliolum cum fructu
300 mg
Each tablet contains 7.5 mg of hydroxyanthracene derivatives, calculated as sennoside B.
Excipients: potato starch, anhydrous colloidal silica.
Labofarm sp. z o.o.
ul. Lubichowska 176B
83-200 Starogard Gdański
tel. 58 561 20 08
e-mail: poczta@labofarm.com.pl
Senefol, 2024.10.18
2 / 2
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.